The use of venetoclax (ABT-199) in the treatment of CLL
Enhancing autologous cellular therapy with ibrutinib in CLL patients
Iris de Weerdt
Side effects of novel drugs and managing patient expectations in CLL
Navigating advances in the myeloma landscape over the past couple of years
Why do charities need to keep funding research into leukemia and blood cancer in general?